Please login to the form below

Not currently logged in
Email:
Password:

cell therapies

This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.

GSK hands rare disease assets over to Orchard

GSK hands rare disease assets over to Orchard

gene and cell therapies, including University College London; Great Ormond Street Hospital; the University of Manchester; the University of California Los Angeles; and Boston Children’s Hospital. ... Those target mucopolysaccharidosis type 1 (MPS1 or

Latest news

  • Gilead signs $3bn-plus gene-editing deal with Sangamo Gilead signs $3bn-plus gene-editing deal with Sangamo

    Gilead signs $3bn-plus gene-editing deal with Sangamo. Will use the platform for new cell-based cancer therapies. ... The company seems determined to stay in the forefront of the pharma industry’s push into cell therapies, with the latest deal coming

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    of cell-based therapies in these areas at a time when its biggest earner Revlimid is a few years away from patent expiry and generic competition. ... If CAR-T is shown to be effective in solid tumours that would be a massive boost to all players in

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    That alliance covers chimeric antigen receptor T cell (CAR-T) therapies, including Juno’s lead candidate JCAR017 which is in the final stages of development and could get its first approvals ... medicinal products such as cell and gene therapies.

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Takeda offers 520m for stem cell firm TiGenix. The deal will go ahead if the Japanese pharma company can secure an 85% stake in the biotech. ... We believe that TiGenix’s expertise would help accelerate Takeda’s ambition to develop novel stem cell

  • New NHS Alliance launches healthcare TV programme New NHS Alliance launches healthcare TV programme

    Presented by newsreader Natasha Kaplinksy, the news-style piece will combine key interviews, case studies and sponsored stories from Bristol-Myers Squibb, Cell &Gene Therapy Catapult, and Novartis to name a ... disease cures and innovative cell and gene

More from news
Approximately 2 fully matching, plus 74 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like

  • Can UK pharma rise to the post-Brexit challenge? Can UK pharma rise to the post-Brexit challenge?

    to deliver a medicine, and it is much easier to secure funding for stem cell research for developing advanced therapies in the UK compared to the US.

  • Deal Watch March 2017 Deal Watch March 2017

    Sartorius. Acquisition. Platform, instrumentation, software and reagents for real-time live cell analysis. ... Sanford Health. Strategic financing. Cell-based therapies for rotator cuff injuries and venous ulcer treatments.

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    The NICE appraisal methods and decision framework are applicable to regenerative medicines and cell therapies. ... Local funding questions remain unanswered. Questions remain as to how treatment centres are to be funded for cell therapies.

  • Deal Watch January 2017 Deal Watch January 2017

    Immatics. Amgen. Licence / joint development. Next-generation, T-cell engaging bispecific immuno-therapies . ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Turnstone Biologics bolsters leadership team Turnstone Biologics bolsters leadership team

    Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... Prior to Novartis Perry was global head of R&D for the bioscience division at Baxter Healthcare, vice president of

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    In parallel, apceth’s pipeline has recently entered a very thrilling phase, encouraging us to accelerate further the development of our first-in-class, first-in-man cell-based gene therapies.”. ... Moreover, Dusan’s experience will strongly promote

  • Neon Therapeutics taps Dr Richard Gaynor for R&D leadership role Neon Therapeutics taps Dr Richard Gaynor for R&D leadership role

    At Cambridge, US-based Neon he will be tasked with guiding the immuno-oncology company's research programmes, which are focused on developing neoantigen-based therapeutic vaccines and T cell therapies.

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... Dr Stout said: “ I'm eager to roll up my sleeves to prepare SanBio's promising cell

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics